Ear acupressure could replace standard drugs for chemo nausea
NCT ID NCT07716176
First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time
Summary
This study tests whether ear acupressure (stimulating specific points on the ear with bean seeds) combined with a low dose of dexamethasone can prevent nausea and vomiting caused by a common chemotherapy regimen (docetaxel plus cyclophosphamide) in breast cancer patients. Participants are randomly assigned to receive either the acupressure-plus-dexamethasone approach or the standard antiemetic drug regimen. The goal is to see if the acupressure method works as well as standard drugs, with fewer side effects and better quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- auricular point stimulation (acupressure with bean seeds) plus dexamethasone
- What this could lead to
- If effective, this approach could offer a drug-sparing, low-cost way to manage chemotherapy-induced nausea and vomiting, improving quality of life during breast cancer treatment.
- What could go wrong
- This is a small, single-center trial, and the non-inferiority design means it may not prove superiority. Results may not apply to other chemotherapy regimens or cancer types.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 74 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2025
- Expected to finish
-
Dec 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients must meet the following inclusion criteria for the study:\* Age ≥ 18 years and ≤ 85 years\* After a radical mastectomy, further postoperative adjuvant chemotherapy with docetaxel combined with cyclophosphamide regimen is required.\* ECOG performance status score of 0-2.\* Normal hematological function (platelet count \> 80×10⁹/L; white blood cell count \> 3×10⁹/L; neutrophil count \> 1.5×10⁹/L).\* Serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), and transaminase ≤ 5 times the ULN.\* No ascites, no gastrointestinal obstruction, normal coagulation function, and serum albumin ≥ 30g/L.\* Child-Pugh classification of liver function is Grade A.\* Serum creatinine \< ULN, or calculated creatinine clearance rate \> 50ml/min. Exclusion Criteria: * Patients who meet any of the following criteria will be excluded from the study: \* Local inflammation or infection of the auricle\* Bleeding tendency or coagulation disorders\* Severe ascites\* Gastrointestinal obstruction\* Hypertensive crisis or hypertensive encephalopathy\* Severe uncontrolled systemic complications such as infection or diabetes mellitus\* Clinically severe cardiovascular diseases, including cerebrovascular accident (within 6 months before enrollment), myocardial infarction (within 6 months before enrollment), hypertension that is not well-controlled despite appropriate medication, unstable angina pectoris, congestive heart failure (NYHA Class 2-4), and cardiac arrhythmias requiring drug treatment\* A history of or physical examination findings indicating central nervous system diseases (e.g., primary brain tumor, epilepsy uncontrolled by standard treatment, any history of brain metastasis or stroke)\* Hypersensitivity to any drugs used in the study\* Pregnant or lactating women\* Presence of any other diseases, functional impairment caused by metastatic lesions, or suspicious disorders identified during physical examination, which suggest contraindications to the study drugs or place the patient at high risk of treatment-related complications\* Inability or unwillingness to comply with the study protocol.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Breast cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Second Affiliated Hospital of Zhejiang University School of Medicine
RECRUITINGHangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Retrospective analysis of pyrotinib in the treatment of HER2-Positive advanced breast cancer previously treated with trastuzumab and pertuzumab
- Mind and body: does resilience leave a molecular mark in breast cancer?
- Which pain block works better for breast surgery?
- Can a Triple-Drug combo erase HER2-Positive breast tumors before surgery?
- Bacteria inside tumors may hold the key to breast cancer treatment
- Can a newer drug ease the bone pain of chemotherapy support?